Sun Yat-sen University: Nasopharyngeal Carcinoma trials

The registry lists 207 Nasopharyngeal Carcinoma studies with Sun Yat-sen University as lead sponsor. 84 are open to participants now and 2 have results posted.

Early Phase 1 1Phase 1 11Phase 2 87Phase 3 70No phase 48(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Deep Learning Model for Diagnosis and Contour of Cervical Lymph Node for Nasopharyngeal CarcinomaStatus unknownNCT05231616
• A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal NecrosisStatus unknownNCT05228093Not applicable
• Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal CarcinomaActive, not recruitingNCT05211232Phase 3
• Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal CarcinomaActive, not recruitingNCT05201859Phase 2
• Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT05193617Phase 2
• Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT05162872Phase 2
• Olfactory Change After Chemo-radiotherapy for Nasopharyngeal CarcinomaStatus unknownNCT05146050
• Verification of Harmonization of Plasma Epstein-Barr Virus DNA MeasurementsStatus unknownNCT05037357
• Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated RadiotherapyCompletedNCT05020067Phase 2
• Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical StudyStatus unknownNCT05008471Not applicable
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Phase 3
• Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation StudyActive, not recruitingNCT04850235Phase 1
• Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPCCompletedNCT04833257Phase 2
• Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal CarcinomaStatus unknownNCT04764149
• Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal CarcinomaCompletedNCT04636632Phase 1
• Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment FailureActive, not recruitingNCT04586088Phase 2
• Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
• A Study of DC-CIK Immunotherapy in the Treatment of Solid TumorsStatus unknownNCT04476641Phase 2
• Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04472403
• Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04456322Phase 3
• Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04405622Phase 2
• Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04398056Phase 2
• Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma PatientsStatus unknownNCT04394091
• uEXPLORER Total-body PET/CT in Nasopharyngeal CarcinomaCompletedNCT04394065
• Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent ChemoradiotherapyActive, not recruitingNCT04384627Phase 3
• Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal CarcinomaActive, not recruitingNCT04223024Phase 2
• Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal CarcinomaCompletedNCT04108338
• Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.Status unknownNCT04073784Phase 1
• EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Active, not recruitingNCT04072107Phase 2
• Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaCompletedNCT03984357Phase 2
• Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal CarcinomaActive, not recruitingNCT03930498Phase 2
• Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC PatientsStatus unknownNCT03925896Phase 1
• Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC PatientsActive, not recruitingNCT03925090Phase 2
• Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line TherapyCompletedNCT03906058Phase 2
• Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma PatientsActive, not recruitingNCT03855020
• IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT03854838Phase 2
• GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03840421Phase 3
• Delineation of Reducing Clinical Target Volume for Early-stage Nasopharyngeal Carcinoma PatientsCompletedNCT03839602Phase 2
• Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal CarcinomaStatus unknownNCT03837808Phase 3
• Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT03708822Phase 2
• Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Phase 3
• Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal CarcinomaStatus unknownNCT03668730Phase 2
• PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03619824Phase 2
• Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPCCompletedNCT03601390
• PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03427827Phase 3
• To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal CarcinomaStatus unknownNCT03346109Not applicable
• Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal CarcinomaStatus unknownNCT03344068Phase 2/3
• Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal CarcinomaActive, not recruitingNCT03321539Phase 3
• TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal CarcinomaActive, not recruitingNCT03306121Phase 3
• Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma PatientsStatus unknownNCT03290820Phase 2
• The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma PatientsStatus unknownNCT03290001
• Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRTCompletedNCT03283293Phase 2
• A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.Status unknownNCT03210389Phase 2
• Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal CarcinomaCompletedNCT03175939Phase 2
• Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal CarcinomaStatus unknownNCT03093649Not applicable
• Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal TissueStatus unknownNCT03048305
• Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03047265Phase 2
• Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by ChemoradiotherapyStatus unknownNCT03045484Not applicable
• Prospective Study for Prognostic Biomarkers of Nasopharyngeal CarcinomaStatus unknownNCT03025854
• Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03020329Phase 2
• EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) PatientsStatus unknownNCT03006588Phase 2/3
• A Study of Nasopharyngeal Carcinoma From GuangdongStatus unknownNCT03003182
• Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC PatientsCompletedNCT02973386Phase 3
• Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02958111Phase 3
• TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal CarcinomaCompletedNCT02940925Phase 3
• ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Phase 2
• Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02871518Phase 2
• Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical TrailTerminatedNCT02789189Phase 2
• Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT02786641Phase 3
• Individualized Elective Neck Irradiation Based on MRI in NPC PatientsCompletedNCT02642107Phase 3
• Endostar for Locally Recurrent Nasopharyngeal CarcinomaStatus unknownNCT02636231Phase 2
• Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy EraCompletedNCT02633202Phase 3
• Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Phase 3
• Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal CarcinomaStatus unknownNCT02627807Not applicable
• Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02621970Phase 3
• Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal CarcinomaStatus unknownNCT02610556Phase 2
• Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma PatientsCompletedNCT02604472
• A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal CarcinomaStatus unknownNCT02512315Phase 3
• The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC PatientsCompletedNCT02505139
• The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRTActive, not recruitingNCT02460887Phase 3
• Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal CarcinomaCompletedNCT02460419Phase 3
• Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT02456506Not applicable
• Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPCStatus unknownNCT02421640Phase 2
• Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal CarcinomaCompletedNCT02360501Phase 2
• Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated RadiotherapyWithdrawnNCT02289807Not applicable
• Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02250599Phase 2
• Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal CarcinomaStatus unknownNCT02211677
• Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02111460Phase 3
• Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT01872962Phase 3
• Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPCStatus unknownNCT01854203Phase 2/3
• Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal CarcinomaStatus unknownNCT01735409Phase 1/2
• GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT01655628Phase 2
• Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal CarcinomaCompletedNCT01616849Phase 2
• Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal CarcinomaCompletedNCT01540136Phase 3
• Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal CarcinomaCompletedNCT01528618Phase 3
• A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid TumorsStatus unknownNCT01462903Phase 1
• Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement UltrasonographyStatus unknownNCT01347424Phase 2
• Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal CarcinomaCompletedNCT01271439Phase 2